NCT04318886 2026-03-13
Lay Coach-Led Early Palliative Care for Underserved Advanced Cancer Caregivers: The Project ENABLE Cornerstone RCT
University of Alabama at Birmingham
Phase 3 Active not recruiting
Clinical Trials
110 trialsNCT05862285 2026-03-13
UmbrellaMAX
Hoffmann-La Roche
Phase 3 Recruiting
NCT06901531 2026-03-11
LUCERNA
Astellas Pharma Inc
Phase 3 Recruiting
NCT03833167 2026-03-10
KEYNOTE-630
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01602380 2026-02-27
FALCON
AstraZeneca
Phase 3 Completed
NCT05377554 2026-02-27
Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery
Alume Biosciences, Inc.
Phase 3 Completed
NCT07441291 2026-02-27
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Peking University People's Hospital
Phase 3 Recruiting
NCT03976362 2026-02-25
KEYLYNK-008
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05303532 2026-02-23
ROSY-D
AstraZeneca
Phase 3 Enrolling by invitation
NCT07023315 2026-02-11
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Akeso
Phase 3 Recruiting
NCT06127407 2026-02-06
CHONQUER
Servier
Phase 3 Recruiting
NCT07385703 2026-02-04
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT03768063 2026-01-29
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06391242 2026-01-21
Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT05053867 2026-01-14
A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT03148418 2026-01-13
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05112965 2026-01-07
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05351294 2026-01-07
Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet
Rutgers, The State University of New Jersey
Phase 3 Suspended
NCT07311057 2026-01-06
Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma Skin Cancer in Inoperable Patients and Not Suitable for Radiotherapy
Mashhad University of Medical Sciences
Phase 3 Enrolling by invitation
NCT05717166 2025-12-31
SABR-SYNC
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 3 Recruiting
NCT05629234 2025-12-24
ROSY-T
AstraZeneca
Phase 3 Active not recruiting
NCT07290491 2025-12-18
SPC
The Methodist Hospital Research Institute
Phase 3 Recruiting
NCT07287592 2025-12-17
Glutamine for the Prophylaxis of Vincristine-induced Neuropathy in Children and Adolescents With Cancer.
Ain Shams University
Phase 3 Not yet recruiting
NCT01579552 2025-11-12
Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer
Memorial Sloan Kettering Cancer Center
Phase 3 Active not recruiting
NCT04464226 2025-11-06
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Bayer
Phase 3 Recruiting
NCT03721341 2025-09-18
SABR-COMET 10
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 3 Active not recruiting
NCT06867705 2025-08-01
RC-102
Resilience
Phase 3 Recruiting
NCT04879368 2025-07-17
INTEGRATEIIb
Australasian Gastro-Intestinal Trials Group
Phase 3 Active not recruiting
NCT05454280 2025-07-08
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
Fox Chase Cancer Center
Phase 3 Recruiting
NCT06961188 2025-05-07
Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT03578081 2025-04-06
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02492711 2025-03-17
SOPHIA
MacroGenics
Phase 3 Completed
NCT03839940 2025-01-29
MIST
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT05261399 2025-01-10
SAFFRON
AstraZeneca
Phase 3 Recruiting
NCT01442246 2024-09-19
Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.
UNICANCER
Phase 3 Active not recruiting
NCT01706939 2024-08-29
The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer
Icahn School of Medicine at Mount Sinai
Phase 3 Active not recruiting
NCT03764293 2024-02-06
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT03952403 2023-08-08
A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Shanghai Henlius Biotech
Phase 3 Unknown
NCT04033354 2023-08-08
A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC
Shanghai Henlius Biotech
Phase 3 Unknown
NCT05872893 2023-07-21
Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone
Immune Oncology Research Institute
Phase 3 Unknown
NCT01968200 2023-06-28
ICOS-ONE
European Institute of Oncology
Phase 3 Unknown
NCT04763135 2023-06-08
MIR-P
Hospices Civils de Lyon
Phase 3 Terminated
NCT04613830 2023-02-03
Continuous Erector Spinae Block for Post Analgesia in Pediatric Patients
Assiut University
Phase 3 Completed
NCT01855451 2022-11-18
HPVOropharynx
Trans Tasman Radiation Oncology Group
Phase 3 Unknown
NCT03665441 2022-10-18
Trybeca-1
ERYtech Pharma
Phase 3 Completed
NCT00625378 2022-09-01
STEP
Bayer
Phase 3 Completed
NCT02773966 2022-07-22
Kypho-IORT vs. EBRT in Spinal Metastases
Universitätsmedizin Mannheim
Phase 3 Terminated
NCT02454855 2022-06-13
MEQAPAG
Centre Jean Perrin
Phase 3 Terminated
NCT02625610 2022-06-09
Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
EMD Serono
Phase 3 Completed
NCT00255138 2022-04-01
Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects
Temple University
Phase 3 Withdrawn